Pharma

Mar 28 2018

Top 50 pharmaceutical companies, top 50 pharmaceutical companies.#Top #50 #pharmaceutical #companies


PharmaLive

The Pulse of the Pharmaceutical Industry

  • Top 50 pharmaceutical companies
  • Top 50 pharmaceutical companies
  • Top 50 pharmaceutical companies
  • Top 50 pharmaceutical companies

  • Top 50 pharmaceutical companies

FDA Expands Approval For Pfizer Cancer Drug Sutent

  • Top 50 pharmaceutical companies

    Mylan Chops Another 200 To 300 Jobs

  • Top 50 pharmaceutical companies

    FDA Approves AstraZeneca Severe Asthma Drug Fasenra

  • Top 50 pharmaceutical companies

    J Price Set At $373,000

  • Top 50 pharmaceutical companies

    FDA Approves Roche Hemophilia Drug Hemlibra

  • Top 50 pharmaceutical companies

    Biogen Throws Another $200 Million At Aducanumab In Amended Deal With Neurimmune

  • Top 50 pharmaceutical companies

    Boehringer, MiNA Therapeutics Forge NASH Deal

  • Top 50 pharmaceutical companies

    Astellas, Universal Cells Announce Collaboration Utilizing Universal Donor Cell Technology

  • Top 50 pharmaceutical companies

    After years of hope and hype, Bristol-Myers Squibb’s centerpiece immuno-oncologic Opdivo is delivering the dollars.

  • Top 50 pharmaceutical companies

    New CEO David Ricks took over Lilly as the company continues to climb out of its post-Cymbalta/Zyprexa rut.

  • Top 50 pharmaceutical companies

    With proven worldwide commercial capabilities and a robust product pipeline, Johnson & Johnson is firmly positioned to continue generating strong, long-term, sustainable growth.

  • Top 50 pharmaceutical companies

    Easily the fastest grower in Merck’s portfolio, the oncology drug Keytruda is piling up dollars and indications at an impressive rate.

  • Top 50 pharmaceutical companies

    Now on its seventh CEO in the last 10 years and in danger of losing its most valuable branded product, Teva is searching for answers.

  • Top 50 pharmaceutical companies

    With sales of Harvoni and Sovaldi falling off, Gilead welcomed two new blockbusters to the company’s portfolio in 2016.

  • Top 50 pharmaceutical companies

    Amgen is featuring an unprecedented collection of new product offerings, including the first-ever biosimilar cancer treatment to receive U.S. marketing clearance.

  • Top 50 pharmaceutical companies

    Sanofi has faith in strategic plans to get the company to new heights despite continued impact from patent expirations.

  • Top 50 pharmaceutical companies

    Pfizer is overcoming patent expirations by developing a steady new stream of products.

  • Top 50 pharmaceutical companies

    Alexion Wins Expanded Approval For Blockbuster Drug Soliris

  • Top 50 pharmaceutical companies

    Merck To Cut 1,800 Jobs, Add 960 In Chronic Care

  • Top 50 pharmaceutical companies

    Novartis Showcases Four Potential Blockbusters From Late-Stage Pipeline

  • Top 50 pharmaceutical companies

    Drugmaker Novo Nordisk Warns Of U.S. Legislation, Cautious On 2018

  • Top 50 pharmaceutical companies

    Although patent expirations continue to depress revenue, AstraZeneca executives believe in the pipeline.

  • Top 50 pharmaceutical companies

    Management set out a series of new priorities to 2020 to improve innovation, performance and trust in GlaxoSmithKline.

  • Top 50 pharmaceutical companies

    2017 is serving as another challenging year for Novartis as the company continues to work through the Gleevec/Glivec patent expirations that began in 2016, but management is confident that a new phase of growth will start in 2018.

  • Top 50 pharmaceutical companies

    While the world’s leading prescription drug Humira still accounts for the majority of AbbVie’s revenue, plenty else is bubbling up at the almost-five-year-old company.

  • Top 50 pharmaceutical companies

    For Bayer, the acquisition of Monsanto is intended to build its Crop Science division; meanwhile two significant approvals and two new hires enhance progress in oncology.

  • Top 50 pharmaceutical companies

    Roche’s Pharmaceuticals and Diagnostics Divisions continue to generate strong performances significantly driven by new product launches, including four new oncology treatments and the company’s first cancer immunotherapy medicine.

  • Top 50 pharmaceutical companies

    Novo Nordisk executives believe that the company is on a path that will create growth in 2017 and beyond.

  • Written by CREDIT


    Leave a Reply

    Your email address will not be published. Required fields are marked *